Interferon-alpha retreatment in chronic hepatitis C.

Abstract

For chronic hepatitis C virus (HCV) infection, interferon-alpha (IFN-alpha) treatment has recently been established. However, the complete responding rate is not higher than 20-25%. The aim of our study was to assess IFN-alpha retreatment in chronic hepatitis C. In summary, during a second cycle of IFN-alpha, 60% of the patients responded to the retreatment. Indeed, a sustained complete response, together with long-lasting normal alanine aminotransferase values and negative serum HCV-RNA, was observed in about 40% of the retreated patients. Future prospective and controlled trials must define the optimal retreatment strategy, as well as the response-predicting factors including HCV genotypes and quantitative HCV-RNA levels.

• Authors: G Gerken, G Teuber, B Goergen, K H Meyer zum Büschenfelde
• Journal: Journal of hepatology (J Hepatol) Vol. 22 Issue 1 Suppl Pg. 118-21 ( 1995) ISSN: 0168-8278 [Print] Netherlands
• PMID: 7602063 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Interferon alpha-2
• Interferon-alpha
• Recombinant Proteins

Topics

• Adult
• Aged
• Chronic Disease
• Female
• Hepatitis C (therapy)
• Humans
• Interferon alpha-2
• Interferon-alpha (therapeutic use)
• Male
• Middle Aged
• Recombinant Proteins
• Treatment Outcome